Literature DB >> 28199071

Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.

Charlotte L Mentzel1,2,3, P Roberto Bakker2,3, Jim van Os2,4, Marjan Drukker2, Glenn E Matroos5, Hans W Hoek6,7,8, Marina A J Tijssen9, Peter N van Harten2,3.   

Abstract

OBJECTIVE: To test the efficacy of current treatment recommendations for parkinsonism and tardive dyskinesia (TD) severity in patients with severe mental illness (SMI).
METHODS: We present an 18-year prospective study including all 223 patients with SMI (as defined by the 1987 US National Institute of Mental Health, which were based on DSM-III-R diagnostic criteria) receiving care from the only psychiatric hospital of the former Netherlands Antilles. Eight clinical assessments (1992-2009) focused on movement disorders and medication use. Tardive dyskinesia was measured by the Abnormal Involuntary Movement Scale and parkinsonism by the Unified Parkinson's Disease Rating Scale. Antipsychotics were classified into first-generation antipsychotic (FGA) versus second-generation antipsychotic (SGA) and high versus low dopamine 2 (D₂) affinity categories. The effect that switching has within each category on subsequent movement scores was calculated separately by using time-lagged multilevel logistic regression models.
RESULTS: There was a significant association between reduction in TD severity and starting/switching to an FGA (B = -3.54, P < .001) and starting/switching to a high D₂ affinity antipsychotic (B = -2.49, P < .01). Adding an SGA to existing FGA treatment was associated with reduction in TD severity (B = -2.43, P < .01). For parkinsonism, stopping antipsychotics predicted symptom reduction (B = -7.76, P < .01 in FGA/SGA-switch model; B = -7.74, P < .01 in D₂ affinity switch model), while starting a high D₂ affinity antipsychotic predicted an increase in symptoms (B = 3.29, P < .05 in D₂ affinity switch model).
CONCLUSIONS: The results show that switching from an FGA to an SGA does not necessarily result in a reduction of TD or parkinsonism. Only stopping all antipsychotics reduces the severity of parkinsonism, and starting an FGA or a high D₂ affinity antipsychotic may reduce the severity of TD. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28199071     DOI: 10.4088/JCP.16m11049

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

Review 1.  Motor System Pathology in Psychosis.

Authors:  Sebastian Walther; Vijay A Mittal
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

Review 2.  Dystonia and leveraging oral pharmacotherapy.

Authors:  Michelle Ann C Sy; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-20       Impact factor: 3.575

Review 3.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 4.  Drug-induced movement disorders.

Authors:  Stephen R Duma; Victor Sc Fung
Journal:  Aust Prescr       Date:  2019-04-01

5.  Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Authors:  Sarah M Debrey; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

6.  Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Authors:  Lydia E Pieters; P Roberto Bakker; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-02-05       Impact factor: 4.157

7.  No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness.

Authors:  Anne B Koopmans; David J Vinkers; Igmar T Poulina; Petra J A Gelan; Ron H N van Schaik; Hans W Hoek; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-08-07       Impact factor: 4.157

8.  Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study.

Authors:  Stephan T Egger; Julio Bobes; Katrin Rauen; Erich Seifritz; Stefan Vetter; Daniel Schuepbach
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

9.  Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.

Authors:  Stanley N Caroff; Fan Mu; Rajeev Ayyagari; Traci Schilling; Victor Abler; Benjamin Carroll
Journal:  BMC Psychiatry       Date:  2018-09-24       Impact factor: 3.630

10.  Assesment of Risk Factors for Tardive Dyskinesia.

Authors:  Melek Kanarya Vardar; Mehmet Emin Ceylan; Bariş Önen Ünsalver
Journal:  Psychopharmacol Bull       Date:  2020-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.